A MODERN APPROACH TO DISEASE MODELING FOR THE DEVELOPMENT OF ONCOLOGY DRUGS

Abstract

Oncological diseases are characterized by the complexity of pathogenesis and demonstrate a number of specific signs, such as uncontrolled proliferation, stimulation of angiogenesis, activation of invasion and metastasis. Molecular genetic testing to examine genetic abnormalities in tumor cells has been increasingly using in oncology. With an accumulation of the data on the repertoire of mutations or other events in the patient’s tumors, new goals for the development of more targeted and specific antitumor therapies appear. For example, membrane proteins EGFR, HER-2, PSMA and C-met are identified as such targets. Despite the large volume of research conducted, no more than 11% of the total drug candidates are approved by regulatory authorities for clinical use. This is often due to their lack of effectiveness and the incomparability of the results obtained in preclinical trials in animal models with actual results in patients. Therefore, the development of experimental approaches for modeling tumor processes in laboratory animals is an urgent problem.